Literature DB >> 19116624

Tetrabenazine.

Michael R Hayden, Blair R Leavitt, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19116624     DOI： 10.1038/nrd2784

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

1.  Tetrabenazine treatment for Huntington's disease-associated chorea.

Authors:  William G Ondo; Ron Tintner; Madhavi Thomas; Joseph Jankovic
Journal:  Clin Neuropharmacol       Date:  2002 Nov-Dec       Impact factor: 1.592

Review 2.  Therapeutic options for Huntington's disease.

Authors:  Yvette A M Grimbergen; Raymund A C Roos
Journal:  Curr Opin Investig Drugs       Date:  2003-01

3.  Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.

Authors:  Rona K Graham; Yu Deng; Elizabeth J Slow; Brendan Haigh; Nagat Bissada; Ge Lu; Jacqueline Pearson; Jacqueline Shehadeh; Lisa Bertram; Zoe Murphy; Simon C Warby; Crystal N Doty; Sophie Roy; Cheryl L Wellington; Blair R Leavitt; Lynn A Raymond; Donald W Nicholson; Michael R Hayden
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

4.  Tetrabenazine in the treatment of hyperkinetic movement disorders.

Authors:  J Jankovic
Journal:  Adv Neurol       Date:  1983

Review 5.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 6.  Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series.

Authors:  Christian Landles; Gillian P Bates
Journal:  EMBO Rep       Date:  2004-10       Impact factor: 8.807

7.  Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects.

Authors:  G P QUINN; P A SHORE; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1959-10       Impact factor: 4.030

8.  Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.

Authors: 
Journal:  Neurology       Date:  2006-02-14       Impact factor: 9.910

9.  Effect of tetrabenazine on extrapyramidal movement disorders.

Authors:  M A Dalby
Journal:  Br Med J       Date:  1969-05-17
  9 in total
  15 in total

1.  Trial watch: NeuroSearch's dopaminergic stabilizer improves movement disorders in Huntington's disease.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

Review 2.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

3.  Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.

Authors:  L Brusa; A Orlacchio; A Stefani; S Galati; M Pierantozzi; C Iani; N B Mercuri
Journal:  Funct Neurol       Date:  2013 Apr-May

Review 4.  Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases.

Authors:  Sarawut Suksuphew; Parinya Noisa
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 5.  Cause or compensation?-Altered neuronal Ca2+ handling in Huntington's disease.

Authors:  James P Mackay; Wissam B Nassrallah; Lynn A Raymond
Journal:  CNS Neurosci Ther       Date:  2018-02-09       Impact factor: 5.243

Review 6.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

7.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

Review 8.  Therapeutic approaches to preventing cell death in Huntington disease.

Authors:  Anna Kaplan; Brent R Stockwell
Journal:  Prog Neurobiol       Date:  2012-08-28       Impact factor: 11.685

9.  Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

Authors:  Keith T Gagnon; Hannah M Pendergraff; Glen F Deleavey; Eric E Swayze; Pierre Potier; John Randolph; Eric B Roesch; Jyoti Chattopadhyaya; Masad J Damha; C Frank Bennett; Christophe Montaillier; Marc Lemaitre; David R Corey
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

10.  Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis.

Authors:  Lindsey R Orgren; Emily E Maverick; Christopher C Marvin
Journal:  J Org Chem       Date:  2015-11-13       Impact factor: 4.354
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.